Company profile: MetaVia Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage multimodal disease-modifying therapies, including DA-1241, an oral GPR119 agonist in Phase 2a for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and DA-1726, a once-weekly dual oxyntomodulin analog agonist targeting GLP1R and GCGR for obesity, with a Phase 1 clinical trial expected to begin in 2024.
Products and services
- Multimodal Disease-Modifying Therapies Development and Commercialization: Architects clinical-stage programs to advance and commercialize multimodal, disease-modifying therapeutics, as a clinical-stage biotechnology company
- DA-1726: A once-weekly injectable dual oxyntomodulin analog agonist targeting GLP1R and GCGR to treat obesity, with Phase 1 clinical trial initiation expected in 2024
- DA-1241: An oral GPR119 agonist engineered for treating MASH and T2DM, currently in Phase 2a clinical trials confirming receptor-mediated metabolic disease modification
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MetaVia Therapeutics
Artara Therapeutics
HQ: United States
Website
- Description: Provider of investigational cell and intravenous therapies, including TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations based on immunopotentiator OK-432, and IV Choline Chloride to address choline deficiency in patients on parenteral nutrition, aiming to be the first FDA-approved IV choline formulation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Artara Therapeutics company profile →
Ysopia Bioscience
HQ: France
Website
- Description: Provider of cutting-edge microbiome-based biotherapies in clinical-stage development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ysopia Bioscience company profile →
Tramontane Therapeutics
HQ: Spain
Website
- Description: Provider of gene therapy solutions for common neurological and metabolic illnesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tramontane Therapeutics company profile →
Zystor
HQ: United States
Website
- Description: Provider of enzyme replacement therapies under development for the treatment of lysosomal storage diseases; privately held biotechnology company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zystor company profile →
Intercept Pharmaceuticals
HQ: United States
Website
- Description: Provider of small molecule drugs and therapeutics for chronic fibrotic and metabolic diseases, including INT-747, an FXR modulating agent for chronic autoimmune liver diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intercept Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MetaVia Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MetaVia Therapeutics
2.2 - Growth funds investing in similar companies to MetaVia Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MetaVia Therapeutics
4.2 - Public trading comparable groups for MetaVia Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →